A nanoparticle formulation.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Other treatment

Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

PDA@Exosome is a nanoparticle formulation derived from hACE2-expressing 293T cells. The nanoparticles contain polydopamine (with antioxidant properties), which has been coated by exosome membrane in the process of exocytosis. PDA@Exosome has been shown to be biocompatible, to bind SARS-CoV-2 Spike protein in vitro, and to reduce Spike-induced lung inflammation in an animal model (Ma et al., 2022).


Supporting references

Link Tested on Impact factor Notes Publication date
HACE2-Exosome-Based Nano-Bait for Concurrent SARS-CoV-2 Trapping and Antioxidant Therapy
Spike protein ACE2 Cell-based therapy Novel compound Biophysical assay Animal model In vitro Mechanism Mixed substance Extracellular vesicles
In vitro; biophysical assay; BALB/c mice 9.23

The formulation was biocompatible. It displayed antioxidative properties and competitively bound SARS-CoV-2 Spike protein in vitro. In a murine model of Spike protein-induced lung inflammation, transtracheal injection of the formulation decreased inflammation and tissue damage.